Chronic obstructive pulmonary disease risk assessment tools: is one better than the others?
- 13 October 2021
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 28 (2) , 99-108
Abstract
Purpose of review: Risk assessment tools are essential in COPD care to help clinicians identify patients at higher risk of accelerated lung function decline, respiratory exacerbations, hospitalizations, and death. Recent findings: Conventional methods of assessing risk have focused on spirometry, patient-reported symptoms, functional status, and a combination of these tools in composite indices. More recently, qualitatively and quantitatively assessed chest imaging findings, such as emphysema, large and small airways disease, and pulmonary vascular abnormalities have been associated with poor long-term outcomes in COPD patients. Although several blood and sputum biomarkers have been investigated for risk assessment in COPD, most still warrant further validation. Finally, novel remote digital monitoring technologies may be valuable to predict exacerbations but their large-scale performance, ease of implementation, and cost effectiveness remain to be determined. Summary: Given the complex heterogeneity of COPD, any single metric is unlikely to fully capture the risk of poor long-term outcomes. Therefore, clinicians should review all available clinical data, including spirometry, symptom severity, functional status, chest imaging, and bloodwork, to guide personalized preventive care of COPD patients. The potential of machine learning tools and remote monitoring technologies to refine COPD risk assessment is promising but remains largely untapped pending further investigation.Keywords
This publication has 75 references indexed in Scilit:
- The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool: Insights from the COPD Biomarker Qualification ConsortiumAmerican Journal of Respiratory and Critical Care Medicine, 2016
- Association between Functional Small Airway Disease and FEV1 Decline in Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2016
- Clinical Significance of Symptoms in Smokers with Preserved Pulmonary FunctionNew England Journal of Medicine, 2016
- Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population StudyAmerican Journal of Respiratory and Critical Care Medicine, 2016
- Prediction of Acute Respiratory Disease in Current and Former Smokers With and Without COPDChest, 2014
- Pulmonary Arterial Enlargement and Acute Exacerbations of COPDNew England Journal of Medicine, 2012
- The Dyspnoea, Obstruction, Smoking, Exacerbation (DOSE) index is predictive of mortality in COPDPrimary Care Respiratory Journal, 2012
- Susceptibility to Exacerbation in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2010
- The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2004
- Dyspnea Is a Better Predictor of 5-Year Survival Than Airway Obstruction in Patients With COPDChest, 2002